Health Status of Transgender Women in French Guiana and Paris (TransGuyane)

NCT ID: NCT04962997

Last Updated: 2023-10-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

46 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-08-06

Study Completion Date

2023-01-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Assessing and comparing the life and health status of transgender or trans women in French Guiana and Paris. Conducting a questionnaire on physical, mental and sexual health, migration history, transition, and STI screening.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Transgender or trans women in French Guiana are not known to the hospital environment and rarely seek care: only about fifteen patients are followed up in the Infectious and Tropical Diseases Unit (UMIT) and the Adult Day Hospital (HDJA) of the Cayenne Hospital Center for Human Immunodeficiency Virus (HIV) infection. There is therefore a lack of knowledge of this population, of their health needs (physical, sexual and mental) but also a lack of assistance in the transition process. However, the violence suffered and the risks of infection are high among transgender women who frequently resort to sex work. In fact, they are said to carry the highest burden of HIV in the world, particularly in South America. The need for HIV prevention among transgender women in South America is great.

There is no bibliography of published works concerning transgender women in French Guiana, whereas there are more and more publications from countries that are geographically close (Brazil, Peru, United States), or even from metropolitan France. It is therefore necessary to address this issue in French Guiana. The population of transgender women followed up at the Bichat Hospital (for HIV infection or as part of a sexual health follow-up) represents one of the largest active files of transgender women in France and offers the opportunity to look at these two populations from a cross-sectional perspective.

The study will be cross-sectional and multicentric (Cayenne in French Guiana, Paris) and will include transgender women who have reached the age of majority and who agree to answer a questionnaire concerning their living and socio-economic conditions, their migration, their physical, sexual and mental health, and their transition process. Data relating to the search for Sexually Transmitted Infection STIs check-up as well as dermatological examination will be studied in particular with the agreement of the participants.

Data relating to the second consultation will be studied in particular (report of results) without systematic follow-up.

Non-interventional research (RIPH category 3). Cross-sectional observational multicentric study: at the CHC (Cayenne, French Guiana) and at Bichat Hospital (Paris).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sexual Health Mental Health

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Transgender women

Major person identifying as a transgender women consulting at Cayenne Hospital (French Guiana) or Bichat Hospital (Paris) between 06/2021 and 10/2022

Data collection

Intervention Type OTHER

Investigator will ensure the completion of a hetero-administered questionnaire which will be carried out in French, English, Portuguese or Spanish depending on the language spoken by the participant, including informations related to Demography and socio-economic conditions, Addictions, Work and studies, Housing, Health coverage, Gender and sexuality, Vulnerabilities and violence, Recourse to care, State of physical health, Mental Health, Prevention and Sexually Transmitted Infections (STIs), Checkup, Transition path and clinical complications and Dermatological problems.

Investigator will collect the data relating to the clinical examination, dermatological examination and the search for STIs (blood and / or urine) carried out in the routine care of the participant in a case report form (CRF).

The estimated duration of the interviews and the consultation is approximately 1 hour and 30 minutes per patient.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Data collection

Investigator will ensure the completion of a hetero-administered questionnaire which will be carried out in French, English, Portuguese or Spanish depending on the language spoken by the participant, including informations related to Demography and socio-economic conditions, Addictions, Work and studies, Housing, Health coverage, Gender and sexuality, Vulnerabilities and violence, Recourse to care, State of physical health, Mental Health, Prevention and Sexually Transmitted Infections (STIs), Checkup, Transition path and clinical complications and Dermatological problems.

Investigator will collect the data relating to the clinical examination, dermatological examination and the search for STIs (blood and / or urine) carried out in the routine care of the participant in a case report form (CRF).

The estimated duration of the interviews and the consultation is approximately 1 hour and 30 minutes per patient.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Person identifying as a transgender woman
* Consulting at Cayenne Hospital (French Guiana) or Bichat Hospital (Paris)
* Between 07/2021 and 10/2022
* Major
* No opposition to the study
* Absence of neurological or psychiatric disorders that prevented understanding of the study and free participation (sequelae of cerebral toxoplasmosis with aphasia, deaf and mute person, active neuro-meningeal opportunistic infections with cognitive impairment…)

Exclusion Criteria

* Minor
* Refusal to participate and/or neurological or psychiatric disorder preventing understanding of the study
* Not be able to answer questions in languages mastered by principal investigator (French, English, Spanish or Portuguese)
* Person under guardianship or curatorship
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bichat Hospital

OTHER

Sponsor Role collaborator

Centre Hospitalier de Cayenne

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chloé BERTIN

Role: PRINCIPAL_INVESTIGATOR

Centre Hospitalier de Cayenne

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hopsitalier Uiversitaire de Bichat

Paris, , France

Site Status

Centre Hospitalier de Cayenne

Cayenne, Guyane Française, French Guiana

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France French Guiana

References

Explore related publications, articles, or registry entries linked to this study.

Baral SD, Poteat T, Stromdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013 Mar;13(3):214-22. doi: 10.1016/S1473-3099(12)70315-8. Epub 2012 Dec 21.

Reference Type BACKGROUND
PMID: 23260128 (View on PubMed)

Grinsztejn B, Jalil EM, Monteiro L, Velasque L, Moreira RI, Garcia AC, Castro CV, Kruger A, Luz PM, Liu AY, McFarland W, Buchbinder S, Veloso VG, Wilson EC; Transcender Study Team. Unveiling of HIV dynamics among transgender women: a respondent-driven sampling study in Rio de Janeiro, Brazil. Lancet HIV. 2017 Apr;4(4):e169-e176. doi: 10.1016/S2352-3018(17)30015-2. Epub 2017 Feb 8.

Reference Type BACKGROUND
PMID: 28188030 (View on PubMed)

Silva-Santisteban A, Eng S, de la Iglesia G, Falistocco C, Mazin R. HIV prevention among transgender women in Latin America: implementation, gaps and challenges. J Int AIDS Soc. 2016 Jul 17;19(3 Suppl 2):20799. doi: 10.7448/IAS.19.3.20799. eCollection 2016.

Reference Type BACKGROUND
PMID: 27431470 (View on PubMed)

Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol. 2010 Aug;39(4):1048-63. doi: 10.1093/ije/dyq057. Epub 2010 Apr 20.

Reference Type BACKGROUND
PMID: 20406794 (View on PubMed)

Operario D, Burton J, Underhill K, Sevelius J. Men who have sex with transgender women: challenges to category-based HIV prevention. AIDS Behav. 2008 Jan;12(1):18-26. doi: 10.1007/s10461-007-9303-y. Epub 2007 Aug 19.

Reference Type BACKGROUND
PMID: 17705095 (View on PubMed)

Pinto RM, Melendez RM, Spector AY. Male-to-Female Transgender Individuals Building Social Support and Capital From Within a Gender-Focused Network. J Gay Lesbian Soc Serv. 2008 Sep 1;20(3):203-220. doi: 10.1080/10538720802235179.

Reference Type BACKGROUND
PMID: 20418965 (View on PubMed)

Reisner SL, Poteat T, Keatley J, Cabral M, Mothopeng T, Dunham E, Holland CE, Max R, Baral SD. Global health burden and needs of transgender populations: a review. Lancet. 2016 Jul 23;388(10042):412-436. doi: 10.1016/S0140-6736(16)00684-X. Epub 2016 Jun 17.

Reference Type BACKGROUND
PMID: 27323919 (View on PubMed)

Poteat T, Wirtz AL, Radix A, Borquez A, Silva-Santisteban A, Deutsch MB, Khan SI, Winter S, Operario D. HIV risk and preventive interventions in transgender women sex workers. Lancet. 2015 Jan 17;385(9964):274-86. doi: 10.1016/S0140-6736(14)60833-3. Epub 2014 Jul 22.

Reference Type BACKGROUND
PMID: 25059941 (View on PubMed)

Operario D, Soma T, Underhill K. Sex work and HIV status among transgender women: systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2008 May 1;48(1):97-103. doi: 10.1097/QAI.0b013e31816e3971.

Reference Type BACKGROUND
PMID: 18344875 (View on PubMed)

Ferreira S Jr, Francisco PMSB, Nogueira PA. [Profile of transvestites and transgender women: tuberculosis and HIV/AIDS in the city of Sao Paulo]. Rev Panam Salud Publica. 2016 Dec;40(6):410-417. Portuguese.

Reference Type BACKGROUND
PMID: 28718489 (View on PubMed)

Zoni AC, Gonzalez MA, Sjogren HW. Syphilis in the most at-risk populations in Latin America and the Caribbean: a systematic review. Int J Infect Dis. 2013 Feb;17(2):e84-92. doi: 10.1016/j.ijid.2012.07.021. Epub 2012 Oct 12.

Reference Type BACKGROUND
PMID: 23063547 (View on PubMed)

Solomon MM, Mayer KH, Glidden DV, Liu AY, McMahan VM, Guanira JV, Chariyalertsak S, Fernandez T, Grant RM; iPrEx Study Team. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial. Clin Infect Dis. 2014 Oct;59(7):1020-6. doi: 10.1093/cid/ciu450. Epub 2014 Jun 13.

Reference Type BACKGROUND
PMID: 24928295 (View on PubMed)

Keshinro B, Crowell TA, Nowak RG, Adebajo S, Peel S, Gaydos CA, Rodriguez-Hart C, Baral SD, Walsh MJ, Njoku OS, Odeyemi S, Ngo-Ndomb T, Blattner WA, Robb ML, Charurat ME, Ake J; TRUST/RV368 Study Group. High prevalence of HIV, chlamydia and gonorrhoea among men who have sex with men and transgender women attending trusted community centres in Abuja and Lagos, Nigeria. J Int AIDS Soc. 2016 Dec 7;19(1):21270. doi: 10.7448/IAS.19.1.21270. eCollection 2016.

Reference Type BACKGROUND
PMID: 27931519 (View on PubMed)

Wickersham JA, Gibson BA, Bazazi AR, Pillai V, Pedersen CJ, Meyer JP, El-Bassel N, Mayer KH, Kamarulzaman A, Altice FL. Prevalence of Human Immunodeficiency Virus and Sexually Transmitted Infections Among Cisgender and Transgender Women Sex Workers in Greater Kuala Lumpur, Malaysia: Results From a Respondent-Driven Sampling Study. Sex Transm Dis. 2017 Nov;44(11):663-670. doi: 10.1097/OLQ.0000000000000662.

Reference Type BACKGROUND
PMID: 28708696 (View on PubMed)

Kojima N, Park H, Konda KA, Joseph Davey DL, Bristow CC, Brown B, Leon SR, Vargas SK, Calvo GM, Caceres CF, Klausner JD. The PICASSO Cohort: baseline characteristics of a cohort of men who have sex with men and male-to-female transgender women at high risk for syphilis infection in Lima, Peru. BMC Infect Dis. 2017 Apr 11;17(1):255. doi: 10.1186/s12879-017-2332-x.

Reference Type BACKGROUND
PMID: 28399798 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TransGuyane

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Madagascar Female Condom Study
NCT00272974 COMPLETED PHASE3